Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03509467 · ClinicalTrials.gov registry record · NA
Using MC1R Genotype to Impact Melanoma Risk Behavior
A NA study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- NA
- Development phase
- 2,054
- Enrollment target
NCT03509467: Completed NA study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
NCT03509467 is a NA study that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 2,054 participants, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (46% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03509467, a NA study, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 2,054 participants
- Enrollment target
Study Summary
The purpose of this study is to examine how different messages about risk of melanoma can impact the way people protect themselves against developing these diseases.
Primary Outcome
Self-reported average hours spent outside during weekdays for the Non-Hispanic White Population
Interventions
- BEHAVIORAL Personalized Information
- BEHAVIORAL Standard Information
- OTHER DNA Extraction Determination of MC1R Genotypes
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,054 participants |
| Start Date | 2015-08-03 |
| Est. Completion | 2021-02-19 |
| Phase | NA |
What the finished NCT03509467 record still lists
NCT03509467 is an interventional study that assigns participants to a tested intervention. Its 2,054 participants enrollment target places it among the larger protocols in the corpus, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (46% higher).
The record links to 0 conditions, and to 3 interventions - of which Personalized Information is the first listed.
NCT03509467 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03509467 about?
NCT03509467 is a clinical study titled "Using MC1R Genotype to Impact Melanoma Risk Behavior". The purpose of this study is to examine how different messages about risk of melanoma can impact the way people protect themselves against developing these diseases.
What is the current status of trial NCT03509467?
This trial is currently completed. It is a NA study. The enrollment target is 2,054 participants. The study started on 2015-08-03. Estimated completion is 2021-02-19.
What interventions are being tested in trial NCT03509467?
The interventions under investigation include: Personalized Information (BEHAVIORAL), Standard Information (BEHAVIORAL), DNA Extraction Determination of MC1R Genotypes (OTHER).
Who is sponsoring clinical trial NCT03509467?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03509467's enrollment target sits among peer trials
2,054 51st of 2000 higher than 1,950 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05050084 · 2,050 participants · Phase 3
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
- NCT05688982 · 2,049 participants · NA
MOLAR: Mapping Oral Health and Local Area Resources
- NCT04871542 · 2,062 participants
Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
- NCT06521944 · 2,062 participants
RSV Vaccine Pregnancy Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI